AngioDynamics (NASDAQ:ANGO) Stock: Insider Stephen Trowbridge Sells 1,720 Shares

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Stephen Trowbridge sold 1,720 shares of the business’s stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $12.17, for a total transaction of $20,932.40. Following the transaction, the chief financial officer directly owned 304,076 shares of the company’s stock, valued at approximately $3,700,604.92. This trade represents a 0.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

AngioDynamics Stock Down 2.9%

NASDAQ ANGO traded down $0.36 on Friday, reaching $11.99. 475,817 shares of the stock traded hands, compared to its average volume of 531,842. AngioDynamics, Inc. has a 12 month low of $9.39 and a 12 month high of $16.29. The firm’s fifty day simple moving average is $14.26 and its 200 day simple moving average is $12.46. The company has a market cap of $504.18 million, a price-to-earnings ratio of -15.37 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm had revenue of $80.92 million for the quarter, compared to analysts’ expectations of $80.51 million. AngioDynamics had a negative net margin of 10.12% and a negative return on equity of 4.49%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, equities research analysts forecast that AngioDynamics, Inc. will post -0.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ANGO. Wall Street Zen lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Thursday, October 15th. HC Wainwright decreased their target price on shares of AngioDynamics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, October 13th. Zacks Research upgraded shares of AngioDynamics from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of AngioDynamics in a report on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, AngioDynamics has an average rating of “Moderate Buy” and an average target price of $19.00.

Institutional Investors Weigh In On AngioDynamics

A number of institutional investors have recently added to or reduced their stakes in ANGO. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of AngioDynamics in the 3rd quarter valued at $40,000. Integrated Wealth Concepts LLC acquired a new position in AngioDynamics in the 2nd quarter valued at about $38,000. Legal & General Group Plc purchased a new position in shares of AngioDynamics in the 2nd quarter valued at about $45,000. Public Employees Retirement System of Ohio purchased a new stake in shares of AngioDynamics in the second quarter valued at about $64,000. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of AngioDynamics by 0.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after purchasing an additional 5,509 shares during the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company that develops and manufactures minimally invasive devices used in vascular access, peripheral vascular disease treatment, oncology and surgical procedures. Its products are designed to support physicians in diagnosing and treating patients while reducing the need for more invasive interventions.

The company’s portfolio includes the Auryon system for atherectomy and thrombectomy procedures, the NanoKnife system, which uses irreversible electroporation technology for the ablation of certain soft-tissue tumors, and devices for vascular access and the management of procedure-related complications.